Healthcare Pharma

Immuno-Oncology : The Latest Frontier in Cancer Therapy

For as long as medicine has existed, cancers have ravaged humanity. The search for an eventual cure has been a tremendous & tireless pursuit, selflessly undertaken by doctors, researchers, scientists & the entire healthcare community.  With each passing year and the availability of sophisticated technologies, their efforts continue to go from strength to strength, expanding […]

Healthcare Pharma

Catch up with Matt Davis’ talk on “Neoantigen Targeted Cancer Immunotherapy in the Clinic” at Advance Genetic Sequencing Virtual Conference 2021

Matt Davis PhD joined Gritstone Oncology (NASDAQ: GRTS) in 2015 and is currently the Director of Molecular Biology and Sequencing responsible for various neo-antigen discovery and translational genomics efforts.  Prior to Gritstone, Dr. Davis conducted post-doctoral research at Warp Drive Bio in the discovery biology group.  He holds a PhD in Genetics from Yale with […]

Healthcare

Discussing the latest IO developments at the 5th Annual MarketsandMarkets Next-Gen Immuno-Oncology Virtual Congress 2021

July, 08th 2021 – 5th Annual MarketsandMarkets Next-Gen Immuno-Oncology Virtual Congress 2021 to be held on the 26th-29th October 2021 will host top tier institutes pharmaceutical, bio-pharmaceutical and biotechnology companies like Scancell, Regeneron Pharmaceuticals, Cancer Vaccines Ltd, Boston Immune Technologies & Therapeutics & more to deliver the key challenges and future directions in IO research […]

Healthcare Pharma

“Tumor-targeted costimulatory trimerbodies for cancer immunotherapy.”- A brief discussion with Juan Perez Villar, CEO, LeadArtis.

Doctor in Immunology from the Autonomous University of Madrid (Spain), extensive international career in the biopharmaceutical industry at Astellas Inc. and Bristol-Myers Squibb Co. (USA). Experienced R&D leader in immune-oncology (IO). Previously, participated in preclinical development of CD28 biologic modulators for inflammatory conditions, small molecule tyrosine kinase inhibitors and fully human antibodies for advanced solid […]

Healthcare Pharma

Héctor Pérez Montoyo, of Ability Pharma discusses his research on, “ABTL0812, a new immunotherapeutic anticancer agent at phase 2b clinical stage.”

Héctor’s work has always focused on understanding the molecular pathophysiological mechanisms leading to autoimmunity and cancer development, investigating mechanism of action of newly developed molecules to treat such diseases. He started his career in 2006 when he moved to UT Southwestern Medical Center in Dallas (EEUU), to carry out this thesis in developing novel therapeutic […]

Healthcare Pharma Technology

Dr. William Williams of Briacell Therapeutics Corporation talks about Personalized, off-the-shelf cellular immunotherapy for cancer

Dr. Williams is the President and CEO of BriaCell Corporation, where he has shepherded Bria-IMT™ into the clinic, established positive proof-of-concept, forged a collaboration with Incyte for novel combinations and coordinated the development of an off-the-shelf personalized approach to cancer immunotherapy. While at Incyte Corporation as Head of Exploratory Development, he brought numerous molecules into […]

Uncategorized

What do MNM Analysts have to say about the Immuno Oncology Market?

Our 4th Annual MarketsandMarkets Next Gen Immuno-Oncology Congress to be held on 12th-13th March 2020 in London, UK would address the challenges and future directions in IO research. The congress aims to bring academicians, researchers and scientists from research institutes, pharmaceutical, bio-pharmaceutical, and biotechnology companies to discuss the latest updates in the development of ADC’s, Bispecific Antibodies, Cellular Therapy, […]